Brief: ImmunoGen To Collaborate With Gilead To Evaluate Pivekimab With Magrolimab

ImmunoGen

09/12/2022 12:56

Dec 9 (Reuters) - ImmunoGen Inc  IMGN.O :
    * IMMUNOGEN ANNOUNCES CLINICAL COLLABORATION WITH GILEAD TO
EVALUATE PIVEKIMAB SUNIRINE IN COMBINATION WITH MAGROLIMAB IN
RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
    * IMMUNOGEN INC- EXPECTED TO INITIATE IN 2023, COLLABORATION
WILL
BE A NEW COHORT IN IMMUNOGEN'S 802 STUDY

Source text for Eikon:  ID:nBw1bdjDja 
Further company coverage:  IMGN.O 
 ((Reuters.Briefs@thomsonreuters.com;))